Avatar
Cicadaeffect

0 Following 0 Followers
1
Ion as a prognostic marker in breast cancer were based on non-randomized retrospective analyses in three small, breast cancer cohorts from Nijmegen (The Netherlands) and still required independent validation. In this study, we provide a higher level of evidence as we confirm that mRNA expression values of DC-SCRIPT indicate outcome in an independent retrospective cohort of 1,505 primarySieuwerts e
1
Ion as a prognostic marker in breast cancer were based on non-randomized retrospective analyses in three small, breast cancer cohorts from Nijmegen (The Netherlands) and still required independent validation. In this study, we provide a higher level of evidence as we confirm that mRNA expression values of DC-SCRIPT indicate outcome in an independent retrospective cohort of 1,505 primarySieuwerts e
1
Ith DFS, MFS, OS, and PFS, respectively. In multivariable analysis, Cox proportional hazards models for DFS, MFS, OS, and PFS were applied to test DCSCRIPT levels added to models with traditional factors. The proportional hazards assumptions were checked with Schoenfeld residuals. The analyses were stratified if necessary. The models for DFS, MFS, and OS for LNN patients who had not received adjuv
1
Ship between DC-SCRIPT mRNA levels measured in primary breast cancers and tumor aggressiveness in a much larger, independent, breast cancer cohort. The main clinical endpoints for assessing the prognostic value of DC-SCRIPT expression were disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS) in lymph node-negative (LNN) patients who had not received adjuvant syste
1
Receptors also modulate response to therapy [8,9], we also assessed, as a secondary aim of this study, the predictive value of DC-SCRIPT by using clinical benefit and progression-free survival (PFS) after first-line tamoxifen for advanced disease as the main endpoints.Materials and methodsPatientsdetermined by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) [14,16,17]. Follow-up
1
Ship between DC-SCRIPT mRNA levels measured in primary breast cancers and tumor aggressiveness in a much larger, independent, breast cancer cohort. The main clinical endpoints for assessing the prognostic value of DC-SCRIPT expression were disease-free survival (DFS), metastasis-free survival (MFS), and overall survival (OS) in lymph node-negative (LNN) patients who had not received adjuvant syste
1
Noma in situ; DC-SCRIPT, dendritic cell-specific transcript gene; ERBB2+, HER2neu-positive; ESR, estrogen receptor gene; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; PGR, progesterone receptor gene; pT1, small tumor without lymphatic/vascular invasion.(Spearman's rho = 0.87; P
1
Noma in situ; DC-SCRIPT, dendritic cell-specific transcript gene; ERBB2+, HER2neu-positive; ESR, estrogen receptor gene; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular carcinoma; PGR, progesterone receptor gene; pT1, small tumor without lymphatic/vascular invasion.(Spearman's rho = 0.87; P
1
Ity Nijmegen Medical Centre, Geert Grooteplein 28, Nijmegen, 6525 GA, The Netherlands Full list of author information is available at the end of the articleof breast cancers. Apart from breast epithelial tumor cells, ESR2 is also expressed in adjacent infiltrating lymphocytes, fibroblasts, and endothelial cells, all of which are known to influence tumor growth [3]. However, its precise role in bre
1
IcsResultsAssociations of DC-SCRIPT with clinicopathological factors and histological and intrinsic breast cancer subtypesThe relationship between DC-SCRIPT and patient and tumor characteristics was investigated with the use of non-parametric methods (Spearman rank correlations for continuous variables and Wilcoxon rank-sum for dichotomized or Kruskal-Wallis test for ordered variables). To reduce